These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 21621683)

  • 1. The case against BRCA 1 and 2 testing.
    Lin C; Sasaki T; Strumwasser A; Harken A
    Surgery; 2011 Jun; 149(6):731-4. PubMed ID: 21621683
    [No Abstract]   [Full Text] [Related]  

  • 2. BRCA testing is important for our patients.
    Anderson BO; Javid SH; Calhoun KE; Byrd DR
    Surgery; 2012 Apr; 151(4):637-8. PubMed ID: 22306834
    [No Abstract]   [Full Text] [Related]  

  • 3. Critique of "Evidence-Based Surgical Hypothesis: The case against BRCA1 and 2 testing".
    Nussbaum RL
    Surgery; 2012 Apr; 151(4):634-7. PubMed ID: 22306835
    [No Abstract]   [Full Text] [Related]  

  • 4. [Genetic testing in patients at risk for carcinoma of the breast].
    Kiechle M
    Dtsch Med Wochenschr; 2006 Oct; 131(43):2420-2. PubMed ID: 17054060
    [No Abstract]   [Full Text] [Related]  

  • 5. Tissue-based predictors of germ-line BRCA1 mutations: implications for triaging of genetic testing.
    de la Cruz J; Andre F; Harrell RK; Bassett RL; Arun B; Mathieu MC; Delaloge S; Gilcrease MZ
    Hum Pathol; 2012 Nov; 43(11):1932-9. PubMed ID: 22591913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High risk of contralateral breast carcinoma in women with hereditary/familial non-BRCA1/BRCA2 breast carcinoma.
    Shahedi K; Emanuelsson M; Wiklund F; Gronberg H
    Cancer; 2006 Mar; 106(6):1237-42. PubMed ID: 16475207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylactic and therapeutic mastectomy in BRCA mutation carriers: can the nipple be preserved?
    Reynolds C; Davidson JA; Lindor NM; Glazebrook KN; Jakub JW; Degnim AC; Sandhu NP; Walsh MF; Hartmann LC; Boughey JC
    Ann Surg Oncol; 2011 Oct; 18(11):3102-9. PubMed ID: 21947588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Model-based predictions of BRCA1/2 mutation status in breast carcinoma patients treated at an academic medical center.
    Shannon KM; Lubratovich ML; Finkelstein DM; Smith BL; Powell SN; Seiden MV
    Cancer; 2002 Jan; 94(2):305-13. PubMed ID: 11900216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA screening.
    Med Lett Drugs Ther; 2007 Nov; 49(1274):93-4. PubMed ID: 18007543
    [No Abstract]   [Full Text] [Related]  

  • 10. Breast cancer susceptibility testing: past, present and future.
    Goldberg JI; Borgen PI
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1205-14. PubMed ID: 16925486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
    Adem C; Reynolds C; Soderberg CL; Slezak JM; McDonnell SK; Sebo TJ; Schaid DJ; Myers JL; Sellers TA; Hartmann LC; Jenkins RB
    Cancer; 2003 Jan; 97(1):1-11. PubMed ID: 12491499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening of BRCA1/2 Mutations Using Direct Sequencing in Indonesian Familial Breast Cancer Cases.
    Anwar SL; Haryono SJ; Aryandono T; Datasena IG
    Asian Pac J Cancer Prev; 2016; 17(4):1987-91. PubMed ID: 27221885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-risk human papilloma virus infection, tumor pathophenotypes, and BRCA1/2 and TP53 status in juvenile breast cancer.
    Aceto GM; Solano AR; Neuman MI; Veschi S; Morgano A; Malatesta S; Chacon RD; Pupareli C; Lombardi M; Battista P; Marchetti A; Mariani-Costantini R; Podestà EJ
    Breast Cancer Res Treat; 2010 Aug; 122(3):671-83. PubMed ID: 19851859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2.
    Domchek SM; Gaudet MM; Stopfer JE; Fleischaut MH; Powers J; Kauff N; Offit K; Nathanson KL; Robson M
    Breast Cancer Res Treat; 2010 Jan; 119(2):409-14. PubMed ID: 19885732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of BRCA1 and BRCA2 mutations in women with breast carcinoma In Situ and referred for genetic testing.
    Hall MJ; Reid JE; Wenstrup RJ
    Cancer Prev Res (Phila); 2010 Dec; 3(12):1579-85. PubMed ID: 21149333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.
    Stadler ZK; Saloustros E; Hansen NA; Schluger AE; Kauff ND; Offit K; Robson ME
    Breast Cancer Res Treat; 2010 Sep; 123(2):581-5. PubMed ID: 20221693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1 and BRCA2: the genetic testing and the current management options for mutation carriers.
    Palma M; Ristori E; Ricevuto E; Giannini G; Gulino A
    Crit Rev Oncol Hematol; 2006 Jan; 57(1):1-23. PubMed ID: 16337408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical management of BRCA1 and BRCA2 mutation carriers.
    Domchek SM; Armstrong K; Weber BL
    Nat Clin Pract Oncol; 2006 Jan; 3(1):2-3. PubMed ID: 16407858
    [No Abstract]   [Full Text] [Related]  

  • 20. Large genomic rearrangements in BRCA1 and BRCA2: implications for patient care.
    Mahon SM
    Oncol Nurs Forum; 2013 May; 40(3):220-2. PubMed ID: 23615136
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.